Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FGFR2 Identified as Rare Target in Fluke-Associated Cholangiocarcinoma

May 5th 2020

FGFR2 fusions are significantly less common in endemic fluke-associated cholangiocarcinoma compared with non–fluke-associated cholangiocarcinoma, demonstrating that distinct etiologies could affect the molecular landscape of cholangiocarcinoma tumors.

Nivolumab Plus Regorafenib Regimen Active in Gastrointestinal Cancers

May 5th 2020

The combination of nivolumab and regorafenib demonstrated promising antitumor activity in patients with gastric and colorectal cancer.

Current and Emerging Treatments for Gastroenteropancreatic Neuroendocrine Tumors

May 4th 2020

During an OncLive® scientific interchange, panelists discussed the current treatment landscape for patients with gastroenteropancreatic-neuroendocrine tumors and the need for improved novel therapies.

Dr. Bekaii-Saab on Moving Metastatic Treatment Strategies to the Adjuvant Setting in CRC

May 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Dr. Hidalgo Medina on the Rationale for Using Patient-Derived Organoids in Pancreatic Cancer

May 2nd 2020

Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses that rationale for using patient-derived organoids (PDOs) in pancreatic cancer.

Encorafenib/Cetuximab Combo Nears EU Approval for BRAF+ mCRC

May 1st 2020

A European panel has recommended approval of encorafenib in combination with cetuximab for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer.

Dr. Mamdani on the Need for Novel Therapies in Locally Advanced Esophageal/GEJ Adenocarcinoma

April 28th 2020

Hirva Mamdani, MD, discusses the need to develop novel therapies in locally advanced esophageal and gastroesophageal junction adenocarcinoma.

Dr. Wang-Gillam on Results of a Phase 1 Study With Defactinib in Pancreatic Ductal Adenocarcinoma

April 28th 2020

Andrea Wang-Gillam, MD, PhD, discusses the results of a phase 1 study with defactinib in patients with pancreatic ductal adenocarcinoma.

Dr. Picozzi on Prognostic Value of Pathologic Response to Chemo in Pancreatic Cancer

April 24th 2020

Vincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.

Dr. Huey on Navigating the Landscape of HCC

April 24th 2020

Ryan W. Huey, MD, assistant professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the landscape of hepatocellular carcinoma (HCC).

Dr. Chung on Adding Dietary Supplements to Chemotherapy in Pancreatic Cancer

April 23rd 2020

Vincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.

Dr. Kaseb on Safety Profile of Atezolizumab Plus Bevacizumab in HCC

April 22nd 2020

Ahmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

ctDNA Identifies Acquired Resistance Mechanisms to Savolitinib in MET+ Gastric Cancer

April 21st 2020

The use of circulating tumor DNA via baseline tumor tissue or rebiopsy led to the identification of several MET mutations previously unidentified upon progression on savolitinib in patients with gastric cancer, as well as MET amplifications as drivers of resistance to the agent during monotherapy treatment of those with MET-amplified disease.

Dr. Janjigian on Extensive Intraoperative Peritoneal Lavage in Gastric Cancer

April 21st 2020

Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.

HCC Armamentarium Expands, But Sequencing and Immunotherapy Issues Remain

April 20th 2020

Ryan W. Huey, MD, highlights the evolving treatment options in the hepatocellular carcinoma paradigm and discusses challenges and next steps in the field.

FDA Approves Pemigatinib for FGFR2+ Cholangiocarcinoma

April 18th 2020

The FDA has approved pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, as detected by an FDA-approved test.

FDA Grants Surufatinib Fast Track Status in pNETS and Other Neuroendocrine Tumors

April 18th 2020

The FDA has granted Fast Track Designations to surufatinib for the treatment of advanced and progressive pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors in patients who are not amenable for surgery.

Dr. Bekaii-Saab on the Need for Umbrella Trials in Biliary Tract Cancer

April 17th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the need for umbrella trials in biliary tract cancer.

Dr. Parikh on Determining Transplant Eligibility in HCC

April 17th 2020

Neehar Parikh, MD, discusses criteria for determining transplant eligibility in hepatocellular carcinoma.

Dr. Choti on the Role of Upfront Surgery in Pancreatic Adenocarcinoma

April 17th 2020

Michael A. Choti, MD, discusses the role of upfront surgery in pancreatic adenocarcinoma.